Tejara Capital Ltd Makes New $2.78 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Tejara Capital Ltd has made a new investment of approximately $2.78 million in Teva Pharmaceutical Industries, acquiring 180,800 shares, which represents 1.1% of its portfolio.
• Other institutional investors have significantly increased their stakes in Teva, with Harel Insurance boosting its holdings by 197,885.2% recently, highlighting increased interest in the company's stock.
• Teva's stock has been given multiple buy ratings from analysts, including a target price of $25.00 from Truist Financial and a consensus price target of $24.71, indicating positive investor sentiment.

Tejara Capital Ltd acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 180,800 shares of the company's stock, valued at approximately $2,779,000. Teva Pharmaceutical Industries accounts for about 1.1% of Tejara Capital Ltd's investment portfolio, making the stock its 27th biggest holding.

Several other large investors also recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after acquiring an additional 134,705 shares during the period. Financial Sense Advisors Inc. boosted its stake in Teva Pharmaceutical Industries by 63.5% in the 1st quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock worth $6,231,000 after purchasing an additional 157,421 shares during the period. King Wealth Management Group boosted its stake in Teva Pharmaceutical Industries by 1,106.9% in the 1st quarter. King Wealth Management Group now owns 175,000 shares of the company's stock worth $2,690,000 after purchasing an additional 160,500 shares during the period. GAMMA Investing LLC boosted its stake in Teva Pharmaceutical Industries by 804.7% in the 1st quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock worth $1,037,000 after purchasing an additional 60,016 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 1.2% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after buying an additional 300,000 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 2.8%

TEVA traded down $0.5050 during mid-day trading on Tuesday, hitting $17.5550. The stock had a trading volume of 12,483,884 shares, compared to its average volume of 12,153,188. The stock's fifty day simple moving average is $16.69 and its 200-day simple moving average is $16.24. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a market capitalization of $20.13 billion, a price-to-earnings ratio of -109.72, a price-to-earnings-growth ratio of 1.06 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period last year, the business posted $0.61 earnings per share. The firm's quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on TEVA. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. Finally, Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $24.71.

Insider Activity

In other news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Insiders sold a total of 65,001 shares of company stock valued at $996,958 in the last quarter. Company insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.